LifeSci Capital downgraded Repare Therapeutics (RPTX) to Market Perform from Outperform.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Repare Therapeutics price target lowered to $4 from $9 at Stifel
- Closing Bell Movers: RH soars 20% on earnings, guidance raise
- Repare Therapeutics Shows Promise in Cancer Drug Trials
- Repare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trial
- Repare Therapeutics announces CRADA to advance camonsertib development